Sclerostin secreted from bone mediates cognitive decline in the brains of aged and Alzheimer's disease mice

Individuals with osteoporosis have increased risk of Alzheimer's disease or cognitive impairment during ageing. We elucidated a partial explanation for bone dysmetabolism's association with such cognitive decline, by demonstrating how elevated sclerostin secretion from osteocytes in bone impaired cognitive function in aged mice and in an Alzheimer's disease mouse model.